SARS-CoV-2 changes lipid profile in the lung epithelial cells by interfering in PPARα and PPARγ expression or activity (Ehrlich et al., 2020), culminating in lipotoxicity, which became these molecules an attractive potential therapeutic target in COVID-19 patients (Heffernan et al., 2020). This evidence concerns the gene PPARG and COVID-19.